NovaBridge Biosciences
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NBP research report →
Range $9 – $9
Price Chart
About the company
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor.
- CEO
- Srishti Gupta
- IPO
- 2020
- Employees
- 30
- HQ
- Rockville, MD, US
Get TickerSpark's AI analysis on NBP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $220.16M
- P/E
- -21.83
- PEG
- -0.27
- P/S
- 0.00
- P/B
- 19.51
- EV/EBITDA
- -45.97
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -0.59%
- ROIC
- -94.82%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-13,476,696
- Net Income
- $-6,614,616+95.9%
- EPS
- $-0.16+96.5%
- OCF Growth
- +94.6%
- FCF Growth
- +94.6%
- 52W High
- $6.79
- 52W Low
- $1.46
- 50D MA
- $1.75
- 200D MA
- $2.85
- Beta
- 1.48
- RSI (14)
- 57
- Avg Volume
- 505.24K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Get the NBP Q2 '26 earnings-call summary
Create a free account to generate an AI summary of this call — key takeaways, results & guidance, CEO/CFO commentary, Q&A, and a bull vs bear read. Ready in about a minute, and it'll be live for everyone.
Create free account →Already have an account? Log in
- Free Float
- 83.8%
- Shares Outstanding
- 50.12M
- Float Shares
- 41.97M
Buy/sell ratio 2.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 5 ETFs
Biggest fund positions in NBP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 8, 26 | Hagler Mark Arnold | other | 949,050 |
| Jul 8, 26 | Lin Liwei Lorraine | other | 254,780 |
| Jul 6, 26 | Gupta Srishti | other | 3,000,000 |
| Jul 1, 26 | Gupta Srishti | other | 0 |
| Jul 4, 26 | Xu Cong Claire | other | 12,432 |
| Jul 6, 26 | Xu Cong Claire | sell | 4,485 |
| Jul 4, 26 | Xu Cong Claire | other | 5,405 |
| Jun 29, 26 | Fu Wei | other | 1,087,720 |
| Jun 29, 26 | Fu Wei | other | 1,010,100 |
| Jun 29, 26 | Fu Wei | other | 725,140 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NBP coverage
Recent articles, reports, and earnings notes.
No research on NBP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NBP report →NovaBridge Biosciences (NBP) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 20
NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution
globenewswire.com · Aug 20
NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
globenewswire.com · Aug 13
Woodside Energy Second Quarter Report for Period Ended 30 June 2026
gurufocus.com · Jul 29
NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026
globenewswire.com · Jul 24
I-Mab (NASDAQ:NBP) Trading Down 4.9% – Time to Sell?
defenseworld.net · Jul 23
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
globenewswire.com · Jun 29
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer
globenewswire.com · Jun 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.